BACTERIOSTATIC ACTIVITY OF SPARFLO® IN VITRO ON MYCOBACTERIA TUBERCULOSIS WITH VARIOUS SPECTRUM OF DRUG RESISTANCE
Abstract
Sparflo® – comparably new antimycobacterial agent of fluoroquinolone group produced by «Dr Reddy´s Laboratory´s Ltd» (India). Sparflo® may be applied in perspective for treatment of multiand extended drug-resistant tuberculosis (MDR and XDR TB). But it´s necessary to know the main farmacologic data of morbidity agent and first of all, its drug sensitivity to Sparflo®.
Article is devoted to the in vitro study of minimal inhibitory concentrations (mcg/ml) and the levels of bacteriostatic activity of Sparflo® in 200 strains of mycobacteria tuberculosis picked out from new detected tuberculosis patients and patients under suspicion on relapse who have various spectrum of drug resistance. These data may help to select strains with the most proper levels of drug resistance.
About the Authors
S. G. Safonova
ГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
I. R. Dorozhkova
ГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
G. E. Freiman
ГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
S. L. Vedenina
«Д-р Редди’c Лабораторис Лтд.»
Russian Federation
Russian Federation
O. O. Kutyrova
«Д-р Редди’c Лабораторис Лтд.»
Russian Federation
Russian Federation
E. M. Bogorodskaya
ГКУЗ города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Туберкулез в Российской Федерации 2010 г. Аналитический обзор статистических показателей, используемых в Российской Федерации. – М., 2011. – 280 с.
2. Guidelines for the programmatic management of drug-resistant tuberculosis / World Health Organization: Geneva, 2008. – (WHO/HTM/TB/2008.402).
3. Guidelines for surveillance of drug resistance in tuberculosis / World Health Organization: Geneva, 2009. – (WHO/HTM/TB/2009.442).
4. Interim recommendations for the surveillance of drug resistance in tuberculosis / World Health Organization: Geneva, 2007. – (WHO/HTM/TB/2007.385).
5. The Internet drug index. 2014. URL: htpp://www.rxlist.com/zagam-drug/clinical-pharmacology.htm (Дата обращения 14.04.2014).
6. Phillips L. TB’s revenge // Nature. – 2013. – Vol. 493. – P. 14-16.
Review
For citations:
Safonova S.G., Dorozhkova I.R., Freiman G.E., Vedenina S.L., Kutyrova O.O., Bogorodskaya E.M. BACTERIOSTATIC ACTIVITY OF SPARFLO® IN VITRO ON MYCOBACTERIA TUBERCULOSIS WITH VARIOUS SPECTRUM OF DRUG RESISTANCE. Tuberculosis and socially significant diseases. 2014;(4):32-36. (In Russ.)
Views:
37
Email this article 